The global Lyme disease diagnostic market size was worth USD 837.2 million in 2022 and is expected to reach 1154.26 million by 2027 with a CAGR of 7.2% from 2022-2027.
Lyme is a bacterial infection caused by Borrelia and spreads over the human body through tick bites. The symptoms associated with Lyme disease are depression, skin diseases like rashes, fatigue, and fever. The disease is treated at the initial stage using antibiotics and if the disease is left untreated, affects the joints, heart, and central nervous system (CNS).
Lyme disease is caused by the bacteria Borreliosis, which is the most common and quickly spreading tick-borne disease globally.
The sudden outbreak of the novel coronavirus (COVID-19) has affected millions of people globally resulting in death. Many businesses including healthcare are affected during the pandemic period. Many healthcare professionals concentrated on combating the virus. Tele consultations and video consultations have come into existence as patients stopped visiting their concerned doctors. Same way, the pandemic has created a negative impact on Lyme disease during the first half of the COVID-19. Later, after the lockdown, people started visiting the hospitals with all necessary safety precautions taken. Post-COVID, there is an increase in the vaccination number for the Lyme disease diagnosis and people feel safe and more protective in visiting the diagnostic centers fueling the market growth.
Increasing patient population
There is an increase in the patient population diagnosed with Lyme disease leading to the growing demand for diagnostic tests driving the Lyme disease diagnostic market growth. The existence of well-developed infrastructure propels market growth. The government has taken some initiatives to improve the healthcare amenities; key players are efficiently making efforts for research and development activities providing opportunities for the Lyme disease diagnostics market.
People are not aware of the disease and the inefficiency of Lyme disease obstructs the Lyme disease diagnostics market growth globally.
Market Size Available
2022 – 2027
2022 – 2027
By Diagnostic Technology, End User, and Region
North America, APAC, Europe, LATAM, MEA
CLICK HERE TO DOWNLOAD SAMPLE
The research report on the global Lyme disease diagnostic market has been segmented and sub-segmented based on diagnostic technology, and end-user.
By diagnostic technology, the serological test segment is dominating the Lyme disease diagnostic market globally. The serological test mainly focuses on puffing out the antibodies generated in response to antigens in the body of an infected person. The serological test involves ELISA, precipitation, agglutination, and western blot procedures that identify infectious diseases.
The PCR analysis segment is the second segment that is growing with the largest share. The segment growth owes to the robust empathy of PCR in identifying infection with Borrelia causing Lyme disease.
The nucleic acid amplification technique is said to have the quickest CAGR rate throughout the forecast period. The growth is due to repeated use in labs to produce different sources of clinical specimens.
By end-user, the hospital's segment is accounted for holding the largest share in the Lyme disease diagnostic market. The easy availability of commercial diagnostic kits for identifying Lyme disease, an increasing number of hospitals with skilled professionals, and well-structured healthcare infrastructure boosts the market growth.
North America is dominating the Lyme disease diagnostic market globally. The region is projected to continue its dominance over the upcoming years. Nearly 3,00,000 people are diagnosed with Lyme disease every year in North America, as per the Centers for Disease Control and Prevention (CDC). The market growth in the region owes to growing expenses in the healthcare sector, and the initial availability of new products. The U.S Lyme disease diagnostic market is driven by factors like a huge patient population and the growing number of Lyme disease diagnostic service providers. Every year in the U.S., around 40,000 cases are recorded, and Lyme disease is the most common vector-borne disease. 80% of the population in eastern Canada is living with Lyme disease.
Europe is considered to rank second in the Lyme disease diagnostics market. Countries like Germany, UK, France, Italy contribute a major share in the global Lyme disease diagnostics market.
Asia-Pacific region is projected to gain substantial growth in the global Lyme disease diagnostics market. The growth in the region is attributed to growing occurrences of Lyme diseases, rising need for superior diagnostic tests for diseases.
Latin America is the second leading region after Asia-Pacific to grow with the quickest CAGR growth rate throughout the historical period. Brazil, Mexico, and the Rest of Latin America support the Lyme disease diagnostics market grow forward. Brazil is expected to lead the market in the region.
The Lyme disease diagnostics market in the Middle East & African region is anticipated to have tremendous growth in the forthcoming years. UAE is said to dominate the market in the region.
Key Market Players
In September 2018, T2 Biosystems, Inc. introduced a new T2Lyme Panel diagnostic procedure for identifying the Lyme disease-0causing bacteria.
In July 2022, PerkinElmer combined with EverlyWell for boosting the innovation in and obtainability of consumer-initiated health testing. The association involves Lyme disease and food sensitivity tests.
Recent Market Developments
Chapter 1. Lyme Disease Diagnostic Market – Scope & Methodology
1.1. Market Segmentation
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Lyme Disease Diagnostic Market – Executive Summary
2.1. Market Size & Forecast – (2021 – 2026) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2021 - 2026
2.3.2. Impact on Supply – Demand
2.3.3. Impact on Production Cost
2.3.4. Impact on Supply Chain
Chapter 3. Lyme Disease Diagnostic Market – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. Lyme Disease Diagnostic Market Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Lyme Disease Diagnostic Market – Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Lyme Disease Diagnostic Market – By Diagnostic Technology
6.1. Serological Test
6.1.2. Western Blot
6.2. Urine Antigen Tests
6.3. Lymphocytic Transformation Test
6.4. Immunofluorescent Staining
6.5. Nucleic Acid Test
Chapter 7. Lyme Disease Diagnostic Market – By End User
7.2. Clinical laboratories
7.3. Physicians Office
Chapter 8. Lyme Disease Diagnostic Market , By Geography – Market Size, Forecast, Trends & Insights
8.1. North America
8.2.7. Rest of Europe
8.3. Asia Pacific
8.3.2. South Korea
8.3.5. Australia & New Zealand
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.3. South America
Chapter 9. Lyme Disease Diagnostic Market – Company Profiles – (Overview, Product Portfolio, Financials, Developments)
9.1. Company 1
9.2. Company 2
9.3. Company 3
9.4. Company 4
9.5. Company 5
9.6. Company 6
9.7. Company 7
9.8. Company 8
9.9. Company 9
9.10. Company 10
Every order comes with Analyst Support
We offer customization to cater your needs to fullest
We value Integrity, quality and authenticity the most